Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

The quest for VEGF and other factors that promote tumour angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these molecules as ...

and small-molecule inhibitors. Many of the US FDA-approved therapies targeting HER-2 and VEGF exhibit unacceptable toxicities, and show problems of efficacy, development of resistance and ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

Anticancer drugs that target proteins involved in tumour angiogenesis, in particular, vascular endothelial growth factor (VEGF), have achieved significant clinical success. Nevertheless, there ...

The approval in adult patients with advanced clear cell RCC that progressed following two or more lines of therapy, including a PD-1 or PD-L1 inhibitor and at least two VEGF targeted therapies, is ...

a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI ...